Amlogenyx research centers around an enzyme called protective protein/cathepsin A, or PPCA, which can break up a form of amyloid beta, the protein many consider responsible for Alzheimer's debilitating effects.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/02/24 | $14,000,000 | Seed |
GordonMD Global Investments | undisclosed |
